>Halozyme sees a good fit for both of Evotec’s business units - Halozyme Therapeutics, Inc. confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE to acquire Evotec for € 11.00 per share in cash, implying a fully diluted equity value of € 2.0bn. The proposal represents a premium of 27% to yesterday’s closing price and a premium of 77% to Evotec's last three-month volume weighted average price on 15 October 2024, th...
>Q3 2024 sales 3.6% higher than our above-market expectation - B&S Group reported a solid Q3 2024, in our view. Sales came in 3.6% higher than our estimate, which we think was the highest in the market. In all divisions except retail, organic sales growth was either higher than expected or significantly better than forecast. Management’s tone on the business was generally positive, and the same applies to the comments about Q4 2024. We forecast 7.1% sales growth in Q4...
The B&S 3Q24 trading update surprised positively on top line performance but disappointed somewhat on costs. 3Q24 revenue was c.8% above our expectations and growth was driven by most business segments. B&S indicated that gross margin decreased in 3Q24, while we expected flat YoY gross margin. Wage costs also increased, this in line with management expectations and our own. As a consequence B&S expects FY24 EBITDA margin to be in the lower half of the 5-6% guidance. We raise our FY24 revenue est...
Die Trendwende deutet sich an. Die Q3-KPIs zeigen erste Umsatz- und Margen-Erholung, denn Kapazitäten steigen und die „Reset“-Sanierungen beginnt Früchte zu tragen (Q3/24: Umsatz €185 +1,5%; EPS € -0,22 (Q3/23: € -0,22)). Der Liquiditätsabfluss ist in Q3 gestoppt. Doch die allgemeine Orderentwicklung ist noch von Zurückhaltung geprägt. Q4/24 soll (projektgetrieben) ein starkes Quartal (inkl. Reset-Einsparungen) werden - die 24er Guidance wird bestätigt.
Springer Nature is one of the world’s leading professional publishing companies. Its highly recurring revenue base and strong market position, good FCF generation and a deleveraging balance sheet should lead to a rerating, we believe. We initiate coverage with an Outperform and a TP of €33. - ...
Springer Nature is one of the world’s leading professional publishing companies. Its highly recurring revenue base and strong market position, good FCF generation and a deleveraging balance sheet should lead to a rerating, we believe. We initiate coverage with an Outperform and a TP of €33. - ...
>Sales beat expectations in Q3 2024; gross margin under pressure - B&S Group reported net sales of € 609.1m in Q3 2024. Organic sales growth amounted to 11.8% in the quarter. Our estimates were € 588m and 7.8%, respectively. There was no consensus available, but from investors we understood that our estimates were the highest. All segment, except the retail segment, strongly outperformed our forecasts. Management added that turnover increased across all segments, whil...
>Q3 sales down 30.4%, y-o-y to € 101.4m below our expectations - Adtran Networks SE (ex. ADVA) released its Q3 2024 results yesterday. Revenues came in at € 101.4m (vs est. at € 110m, i.e. 8% below our expectations). The Q3 2024 decrease stood at 36.4% y-o-y and 6.3% q-o-q due to “reduced demand from major network operators due to their current high inventory levels and the conclusion of several significant customer projects in earlier periods”. Over 9M 2024, revenue...
>Q3 sales down 30.4%, y-o-y to € 101.4m below our expectations - Adtran Networks SE (ex. ADVA) released its Q3 2024 results yesterday. Revenues came in at € 101.4m (vs est. at € 110m, i.e. 8% below our expectations). The Q3 2024 decrease stood at 36.4% y-o-y and 6.3% q-o-q due to “reduced demand from major network operators due to their current high inventory levels and the conclusion of several significant customer projects in earlier periods”. Over 9M 2024, revenue...
>Evotec is confident about a strong Q4 to meet FY guidance - The company appeared quite confident in achieving its 2024 EBITDA guidance of € 15-35m, which requires at least a Q4 adj. EBITDA of € 21.8m after a loss of -€ 6m after nine months. Evotec sees three main drivers for a strong Q4: 1/ a significant increase in sales, which is covered by the current orderbook, this will strongly translate into EBITDA due to high operating leverage, 2/ further cost optimisation w...
EQS-News: Adtran Networks SE / Schlagwort(e): Quartalsergebnis Adtran Networks SE veröffentlicht Ergebnisse für Q3 2024 07.11.2024 / 06:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Übersicht der Kennzahlen für Q3 2024 nach IFRS (ungeprüft) Gewinn- und Verlustrechnung (in Tausend EUR, außer Ergebnis je Aktie und Kennzahlen) Q3 2024 Q3 2023 Veränderung 9M 2024 9M 2023 Veränderung Umsatzerlöse 101.374 145.655 (30,4%) 319.145 495.201 (35,6%) Proforma Bruttoergebnis ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.